These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19874992)

  • 1. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
    Lee JM; Robson MD; Yu LM; Shirodaria CC; Cunnington C; Kylintireas I; Digby JE; Bannister T; Handa A; Wiesmann F; Durrington PN; Channon KM; Neubauer S; Choudhury RP
    J Am Coll Cardiol; 2009 Nov; 54(19):1787-94. PubMed ID: 19874992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 3. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
    Taylor AJ; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Circulation; 2004 Dec; 110(23):3512-7. PubMed ID: 15537681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2.
    Taylor AJ; Zhu D; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Vasc Health Risk Manag; 2007; 3(1):159-64. PubMed ID: 17583186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
    N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3.
    Taylor AJ; Lee HJ; Sullenberger LE
    Curr Med Res Opin; 2006 Nov; 22(11):2243-50. PubMed ID: 17076985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ
    J Am Coll Cardiol; 2010 Jun; 55(24):2721-6. PubMed ID: 20399059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.
    Warnholtz A; Wild P; Ostad MA; Elsner V; Stieber F; Schinzel R; Walter U; Peetz D; Lackner K; Blankenberg S; Munzel T
    Atherosclerosis; 2009 May; 204(1):216-21. PubMed ID: 18822413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report.
    Hippe DS; Phan BAP; Sun J; Isquith DA; O'Brien KD; Crouse JR; Anderson T; Huston J; Marcovina SM; Hatsukami TS; Yuan C; Zhao XQ
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):673-678. PubMed ID: 29301785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
    Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV
    Int J Clin Pract; 2007 Nov; 61(11):1942-8. PubMed ID: 17935553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.